IBDEI026 ; ; 12-MAY-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,1712,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1712,1,3,0)
 ;;=3^Latent nystagmus
 ;;^UTILITY(U,$J,358.3,1712,1,4,0)
 ;;=4^H55.02
 ;;^UTILITY(U,$J,358.3,1712,2)
 ;;=^5006372
 ;;^UTILITY(U,$J,358.3,1713,0)
 ;;=H55.09^^11^144^4
 ;;^UTILITY(U,$J,358.3,1713,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1713,1,3,0)
 ;;=3^Nystagmus NEC
 ;;^UTILITY(U,$J,358.3,1713,1,4,0)
 ;;=4^H55.09
 ;;^UTILITY(U,$J,358.3,1713,2)
 ;;=^87599
 ;;^UTILITY(U,$J,358.3,1714,0)
 ;;=H55.81^^11^144^5
 ;;^UTILITY(U,$J,358.3,1714,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1714,1,3,0)
 ;;=3^Saccadic eye movements
 ;;^UTILITY(U,$J,358.3,1714,1,4,0)
 ;;=4^H55.81
 ;;^UTILITY(U,$J,358.3,1714,2)
 ;;=^5006373
 ;;^UTILITY(U,$J,358.3,1715,0)
 ;;=H55.03^^11^144^6
 ;;^UTILITY(U,$J,358.3,1715,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1715,1,3,0)
 ;;=3^Visual deprivation nystagmus
 ;;^UTILITY(U,$J,358.3,1715,1,4,0)
 ;;=4^H55.03
 ;;^UTILITY(U,$J,358.3,1715,2)
 ;;=^269322
 ;;^UTILITY(U,$J,358.3,1716,0)
 ;;=T36.5X5A^^11^145^1
 ;;^UTILITY(U,$J,358.3,1716,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1716,1,3,0)
 ;;=3^Adverse effect of aminoglycosides, initial encounter
 ;;^UTILITY(U,$J,358.3,1716,1,4,0)
 ;;=4^T36.5X5A
 ;;^UTILITY(U,$J,358.3,1716,2)
 ;;=^5049358
 ;;^UTILITY(U,$J,358.3,1717,0)
 ;;=T36.5X5S^^11^145^2
 ;;^UTILITY(U,$J,358.3,1717,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1717,1,3,0)
 ;;=3^Adverse effect of aminoglycosides, sequela
 ;;^UTILITY(U,$J,358.3,1717,1,4,0)
 ;;=4^T36.5X5S
 ;;^UTILITY(U,$J,358.3,1717,2)
 ;;=^5049360
 ;;^UTILITY(U,$J,358.3,1718,0)
 ;;=T36.5X5D^^11^145^3
 ;;^UTILITY(U,$J,358.3,1718,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1718,1,3,0)
 ;;=3^Adverse effect of aminoglycosides, subsequent encounter
 ;;^UTILITY(U,$J,358.3,1718,1,4,0)
 ;;=4^T36.5X5D
 ;;^UTILITY(U,$J,358.3,1718,2)
 ;;=^5049359
 ;;^UTILITY(U,$J,358.3,1719,0)
 ;;=T45.1X5A^^11^145^5
 ;;^UTILITY(U,$J,358.3,1719,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1719,1,3,0)
 ;;=3^Adverse effect of antineoplastic and immunosup drugs, init
 ;;^UTILITY(U,$J,358.3,1719,1,4,0)
 ;;=4^T45.1X5A
 ;;^UTILITY(U,$J,358.3,1719,2)
 ;;=^5051026
 ;;^UTILITY(U,$J,358.3,1720,0)
 ;;=T45.1X5D^^11^145^6
 ;;^UTILITY(U,$J,358.3,1720,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1720,1,3,0)
 ;;=3^Adverse effect of antineoplastic and immunosup drugs, subs
 ;;^UTILITY(U,$J,358.3,1720,1,4,0)
 ;;=4^T45.1X5D
 ;;^UTILITY(U,$J,358.3,1720,2)
 ;;=^5051027
 ;;^UTILITY(U,$J,358.3,1721,0)
 ;;=T45.1X5S^^11^145^4
 ;;^UTILITY(U,$J,358.3,1721,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1721,1,3,0)
 ;;=3^Adverse effect of antineopl and immunosup drugs, sequela
 ;;^UTILITY(U,$J,358.3,1721,1,4,0)
 ;;=4^T45.1X5S
 ;;^UTILITY(U,$J,358.3,1721,2)
 ;;=^5051028
 ;;^UTILITY(U,$J,358.3,1722,0)
 ;;=T36.8X5A^^11^145^7
 ;;^UTILITY(U,$J,358.3,1722,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1722,1,3,0)
 ;;=3^Adverse effect of other systemic antibiotics, init encntr
 ;;^UTILITY(U,$J,358.3,1722,1,4,0)
 ;;=4^T36.8X5A
 ;;^UTILITY(U,$J,358.3,1722,2)
 ;;=^5049412
 ;;^UTILITY(U,$J,358.3,1723,0)
 ;;=T36.8X5D^^11^145^8
 ;;^UTILITY(U,$J,358.3,1723,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1723,1,3,0)
 ;;=3^Adverse effect of other systemic antibiotics, subs encntr
 ;;^UTILITY(U,$J,358.3,1723,1,4,0)
 ;;=4^T36.8X5D
 ;;^UTILITY(U,$J,358.3,1723,2)
 ;;=^5049413
 ;;^UTILITY(U,$J,358.3,1724,0)
 ;;=T36.8X5S^^11^145^9
 ;;^UTILITY(U,$J,358.3,1724,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1724,1,3,0)
 ;;=3^Adverse effect of other systemic antibiotics, sequela
 ;;^UTILITY(U,$J,358.3,1724,1,4,0)
 ;;=4^T36.8X5S
 ;;^UTILITY(U,$J,358.3,1724,2)
 ;;=^5049414
 ;;^UTILITY(U,$J,358.3,1725,0)
 ;;=T49.6X5A^^11^145^10
 ;;^UTILITY(U,$J,358.3,1725,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1725,1,3,0)
 ;;=3^Adverse effect of otorhino drugs and preparations, init
 ;;^UTILITY(U,$J,358.3,1725,1,4,0)
 ;;=4^T49.6X5A
 ;;^UTILITY(U,$J,358.3,1725,2)
 ;;=^5051926
 ;;^UTILITY(U,$J,358.3,1726,0)
 ;;=T49.6X5D^^11^145^11
 ;;^UTILITY(U,$J,358.3,1726,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1726,1,3,0)
 ;;=3^Adverse effect of otorhino drugs and preparations, subs
 ;;^UTILITY(U,$J,358.3,1726,1,4,0)
 ;;=4^T49.6X5D
 ;;^UTILITY(U,$J,358.3,1726,2)
 ;;=^5051927
 ;;^UTILITY(U,$J,358.3,1727,0)
 ;;=T49.6X5S^^11^145^12
 ;;^UTILITY(U,$J,358.3,1727,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1727,1,3,0)
 ;;=3^Adverse effect of otorhino drugs and preparations, sequela
 ;;^UTILITY(U,$J,358.3,1727,1,4,0)
 ;;=4^T49.6X5S
 ;;^UTILITY(U,$J,358.3,1727,2)
 ;;=^5051928
 ;;^UTILITY(U,$J,358.3,1728,0)
 ;;=T36.95XA^^11^145^13
 ;;^UTILITY(U,$J,358.3,1728,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1728,1,3,0)
 ;;=3^Adverse effect of unsp systemic antibiotic, init encntr
 ;;^UTILITY(U,$J,358.3,1728,1,4,0)
 ;;=4^T36.95XA
 ;;^UTILITY(U,$J,358.3,1728,2)
 ;;=^5049430
 ;;^UTILITY(U,$J,358.3,1729,0)
 ;;=T36.95XD^^11^145^14
 ;;^UTILITY(U,$J,358.3,1729,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1729,1,3,0)
 ;;=3^Adverse effect of unsp systemic antibiotic, subs encntr
 ;;^UTILITY(U,$J,358.3,1729,1,4,0)
 ;;=4^T36.95XD
 ;;^UTILITY(U,$J,358.3,1729,2)
 ;;=^5049431
 ;;^UTILITY(U,$J,358.3,1730,0)
 ;;=T36.95XS^^11^145^15
 ;;^UTILITY(U,$J,358.3,1730,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1730,1,3,0)
 ;;=3^Adverse effect of unspecified systemic antibiotic, sequela
 ;;^UTILITY(U,$J,358.3,1730,1,4,0)
 ;;=4^T36.95XS
 ;;^UTILITY(U,$J,358.3,1730,2)
 ;;=^5049432
 ;;^UTILITY(U,$J,358.3,1731,0)
 ;;=S04.60XA^^11^145^16
 ;;^UTILITY(U,$J,358.3,1731,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1731,1,3,0)
 ;;=3^Injury of acoustic nerve, unspecified side, init encntr
 ;;^UTILITY(U,$J,358.3,1731,1,4,0)
 ;;=4^S04.60XA
 ;;^UTILITY(U,$J,358.3,1731,2)
 ;;=^5020537
 ;;^UTILITY(U,$J,358.3,1732,0)
 ;;=S04.9XXA^^11^145^17
 ;;^UTILITY(U,$J,358.3,1732,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1732,1,3,0)
 ;;=3^Injury of unspecified cranial nerve, initial encounter
 ;;^UTILITY(U,$J,358.3,1732,1,4,0)
 ;;=4^S04.9XXA
 ;;^UTILITY(U,$J,358.3,1732,2)
 ;;=^5020573
 ;;^UTILITY(U,$J,358.3,1733,0)
 ;;=R49.8^^11^145^92
 ;;^UTILITY(U,$J,358.3,1733,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1733,1,3,0)
 ;;=3^Voice and Resonance Disorders NEC
 ;;^UTILITY(U,$J,358.3,1733,1,4,0)
 ;;=4^R49.8
 ;;^UTILITY(U,$J,358.3,1733,2)
 ;;=^5019505
 ;;^UTILITY(U,$J,358.3,1734,0)
 ;;=T36.5X1A^^11^145^19
 ;;^UTILITY(U,$J,358.3,1734,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1734,1,3,0)
 ;;=3^Poisoning by aminoglycosides, accidental, init
 ;;^UTILITY(U,$J,358.3,1734,1,4,0)
 ;;=4^T36.5X1A
 ;;^UTILITY(U,$J,358.3,1734,2)
 ;;=^5049346
 ;;^UTILITY(U,$J,358.3,1735,0)
 ;;=T36.5X1D^^11^145^20
 ;;^UTILITY(U,$J,358.3,1735,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1735,1,3,0)
 ;;=3^Poisoning by aminoglycosides, accidental, subs
 ;;^UTILITY(U,$J,358.3,1735,1,4,0)
 ;;=4^T36.5X1D
 ;;^UTILITY(U,$J,358.3,1735,2)
 ;;=^5049347
 ;;^UTILITY(U,$J,358.3,1736,0)
 ;;=T36.5X1S^^11^145^21
 ;;^UTILITY(U,$J,358.3,1736,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1736,1,3,0)
 ;;=3^Poisoning by aminoglycosides, accidental, sequela
 ;;^UTILITY(U,$J,358.3,1736,1,4,0)
 ;;=4^T36.5X1S
 ;;^UTILITY(U,$J,358.3,1736,2)
 ;;=^5049348
 ;;^UTILITY(U,$J,358.3,1737,0)
 ;;=T36.5X3A^^11^145^22
 ;;^UTILITY(U,$J,358.3,1737,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1737,1,3,0)
 ;;=3^Poisoning by aminoglycosides, assault, initial encounter
 ;;^UTILITY(U,$J,358.3,1737,1,4,0)
 ;;=4^T36.5X3A
 ;;^UTILITY(U,$J,358.3,1737,2)
 ;;=^5049352
 ;;^UTILITY(U,$J,358.3,1738,0)
 ;;=T36.5X3D^^11^145^23
 ;;^UTILITY(U,$J,358.3,1738,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1738,1,3,0)
 ;;=3^Poisoning by aminoglycosides, assault, subsequent encounter
 ;;^UTILITY(U,$J,358.3,1738,1,4,0)
 ;;=4^T36.5X3D
 ;;^UTILITY(U,$J,358.3,1738,2)
 ;;=^5049353
